WallStSmart

High Tide Inc (HITI)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 8883% more annual revenue ($56.58B vs $629.85M). NVS leads profitability with a 23.9% profit margin vs -7.4%. NVS earns a higher WallStSmart Score of 51/100 (C-).

HITI

Avoid

30

out of 100

Grade: F

Growth: 6.0Profit: 3.5Value: 5.0Quality: 3.0
Piotroski: 1/9Altman Z: 0.68

NVS

Buy

51

out of 100

Grade: C-

Growth: 3.3Profit: 9.0Value: 4.0Quality: 5.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HITI.

NVSSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$109.60

Current Price

$147.85

$38.25 premium

UndervaluedFair: $109.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HITI1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
25.2%8/10

Revenue surging 25.2% year-over-year

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$282.11B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
34.9%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability
30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability
23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality
$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

HITI4 concerns · Avg: 3.0/10
Market CapQuality
$224.14M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.3%3/10

Operating margin of 2.3%

Debt/EquityHealth
1.713/10

Elevated debt levels

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

NVS4 concerns · Avg: 3.0/10
PEG RatioValuation
2.484/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Revenue GrowthGrowth
-0.7%2/10

Revenue declined 0.7%

EPS GrowthGrowth
-9.3%2/10

Earnings declined 9.3%

Comparative Analysis Report

WallStSmart Research

Bull Case : HITI

The strongest argument for HITI centers on Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : HITI

The primary concerns for HITI are Market Cap, Operating Margin, Debt/Equity. Debt-to-equity of 1.71 is elevated, increasing financial risk.

Bear Case : NVS

The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.

Key Dynamics to Monitor

HITI profiles as a growth stock while NVS is a declining play — different risk/reward profiles.

HITI carries more volatility with a beta of 1.02 — expect wider price swings.

HITI is growing revenue faster at 25.2% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 30/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

High Tide Inc

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

High Tide Inc. is a vertically integrated company in the cannabis market in Canada, the United States and internationally. The company is headquartered in Calgary, Canada.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?